<DOC>
	<DOCNO>NCT01579474</DOCNO>
	<brief_summary>The aim trial evaluate safety efficacy BI 201335 give 12 24 week combination PegIFN alfa-2b/RBV give 24 48 week chronic genotype 1 hepatitis C virus infect treatment-naïve treatment-experienced Japanese patient</brief_summary>
	<brief_title>Japanese Pegylated Interferon ( PegIFN ) Alfa-2b/Ribavirin ( RBV ) Combination Trial</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Inclusion criterion : 1 . Chronic hepatitis C infection , diagnose positive antiHCV antibody detect HCV RNA screen addition : positive antiHCV antibody detect HCV RNA least 6 month screen ; , liver biopsy consistent chronic HCV infection . 2 . HCV genotype 1 infection confirm genotypic test screen 3 . ( For Cohort 1 ) Therapynaïve interferon , pegylated interferon , ribavirin ( For Cohort 2 ) Confirmed prior virological failure ( null response , partial response , breakthrough relapse ) approve dose PegIFN alfa/RBV IFN beta/RBV least 12 week 8week washout period screen 4 . HCV RNA = 100,000 IU/mL screen 5 . Documentation liver biopsy within 3 year fibroscan within 6 month randomization ( Visit 2 ) 6 . Age 20 70 year 7 . Female patient infertile childbearing potential negative pregnancy test agree use one accept method birth control addition use condom male partner . Male patient infertile , without pregnant female partner consistently correctly use condom . 8 . Signed informed consent form trial participation Exclusion criterion : 1 . HCV infection mixed genotype ( 1/2 , 1/3 , 1/4 ) diagnose genotypic test screening , 2 . Evidence acute chronic liver disease due cause chronic HCV infection . Steatosis diagnose incidentally ( e.g . biopsy ) without clinical relevance exclusion criterion . 3 . HIV coinfection , 4 . Hepatitis B virus ( HBV ) infection base presence hepatitis B surface antigen ( HBsAg ) , 5 . Active malignancy , history malignancy within last 5 year prior screen ( exception appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix ) , 6 . Active , history alcohol illicit drug abuse within past 12 month , 7 . A condition define one opinion investigator may put patient risk participation study , may influence result study , limit patient 's ability participate study , 8 . Usage investigational drug within 30 day prior screen , plan usage investigational drug course study , 9 . Received concomitant systemic antiviral , hematopoietic growth factor , immunomodulatory treatment within 30 day prior screen . Patients treat oral antiviral acyclovir , famciclovir valacyclovir recurrent herpes simplex infection ; oseltamivir zanamivir influenza A infection , may screen , 10 . Received silymarin ( milk thistle ) , glycyrrhizin ( Stronger NeoMinophagen C ; SNMC ) , Shosaikoto ( SST ) within 28 day prior randomization ( Visit 2 ) throughout treatment phase trial , 11 . ( For Cohort 2 ) Patients previously treat least one dose antiviral immunomodulatory drug ( pegylated ) interferon alfa , interferon beta ribavirin acute chronic HCV infection include restricted protease polymerase inhibitor , 12 . Known hypersensitivity ingredient study drug , 13 . Alpha fetoprotein value &gt; 100 ng/mL screening ; &gt; 20 ng/mL =100 ng/mL , patient may include evidence liver cancer appropriate imaging study ( e.g. , ultrasound , CT scan , MRI ) within last 6 month prior randomization ( Visit 2 ) , Other exclusion criterion relate pegylated interferon and/or ribavirin restriction list .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>